News

European equities traded in the US as American depositary receipts kicked off the week higher late M

NVO says real-world data show Ozempic 2 mg matches Eli Lilly's Mounjaro on glucose control and is linked to a higher likelihood of meaningful weight loss.

NVO's oral Wegovy launch is off to a blistering start, topping 3 million prescriptions in five months and drawing many first-time GLP-1 users.

Novo Nordisk (NYSE:NVO) has entered a clinical supply agreement with Veru to test a combination of Wegovy and enobosarm in an obesity trial focused on older adults. The company also presented new semaglutide data at the American Diabetes Association Scientific Sessions on health effects beyond weight loss. The stock most recently closed at $42.96, with the share price down 18.0% year to date and down 41.2% over the past year. Novo Nordisk, trading under NYSE:NVO, is drawing attention as it...

More than 80% of new Wegovy pill prescriptions are for patients who had never previously taken a GLP-1 drug

At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.

Novo Nordisk (NYSE:NVO) shares fell 3% on Monday as investors digested new data and commercial updates presented by the company during the American Diabetes Association (ADA) conference over the weekend. While the event featured encouraging clinical findings for Novo’s next-generation diabetes therapies, analysts said the overall readout provided little that would materially alter the company’s near-term competitive position.

The weight-loss rivals provided positive updates on their obesity treatments but to differing reactions among investors.

Momentum is building to bring a next-generation weight loss drug to market, which could set up these three biotechs to strike a deal with a larger pharma.

The Danish drugmaker said the pill hit one million prescriptions 12 weeks after reaching U.S. pharmacies and online providers, and reached a further two million prescriptions in the following 10 weeks.

Veru (VERU) stock has not been easy to own. The little biotech has spent years persuading investors that its experimental obesity technique can matter in a market dominated by giants. That's a tough sell with Novo Nordisk (NVO) and Eli Lilly (LLY) already owning the narrative with blockbuster ...

Novo Nordisk could maintain this latest early-mover advantage longer than you think.

Novo Nordisk (CPSE:NOVO B) reported positive phase 2 data for its investigational drug amycretin (zenagamtide), a dual GLP-1 and amylin receptor agonist. The phase 2 trial in adults with type 2 diabetes showed strong glycemic control and significant weight loss, with no clear plateau at higher doses. Safety and efficacy data support moving amycretin into phase 3 trials for both diabetes and obesity. This is the first major update on this new pipeline candidate as Novo Nordisk seeks to...

Investing.com -- Pfizer Inc (NYSE:PFE) has unveiled detailed strategy plans and clinical data for its experimental weight-loss injection, aiming to secure a foothold in a competitive market currently dominated by rivals. The New York-based pharmaceutical giant is working to catch up to industry leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO), which have captured significant market share through their first-mover advantages. Following earlier clinical setbacks, Pfizer rev

Investors appear to have left Novo Nordisk behind as they focus on Eli Lilly; that could be a mistake.

Both drugmakers are expanding internationally as pricing and access remain major barriers.

TD Cowen raises its 2030 GLP-1 sales forecast as Lilly and Novo are expected to keep dominant market shares.

Eli Lilly and Company (NYSE:LLY) was among Jim Cramer’s stock calls on Mad Money, as he highlighted several opportunities in out-of-favor sectors. Cramer mentioned the stock while discussing the woes of the healthcare industry, as he said: Next worst is healthcare. Oh, this group has just been annihilated. I’ve never seen it trading this bad […]

LLY's 2026 deal-making spree spans vaccines, oncology and neuroscience, aiming to diversify growth beyond GLP-1s amid rising obesity competition.

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Eli Lilly stock gains 14% in a month as strong Q1 results, obesity drug coverage expansion and promising retatrutide data fueled momentum.

TD Cowen expects around 59 million patients worldwide to be using GLP-1 therapies by the end of the decade, up sharply from its previous estimate of 46 million.

Novo Nordisk (CPSE:NOVO B) has signed a clinical supply agreement with Veru Inc. to provide Wegovy for a Phase 2b obesity trial in older adults. The PLATEAU study will test Wegovy alongside Veru’s enobosarm, a selective androgen receptor modulator, in combination therapy. Novo Nordisk retains no development rights to enobosarm but has secured a right of first negotiation for potential future collaborations with Veru. For investors tracking CPSE:NOVO B, this agreement comes as the share...

Veru will evaluate enobosarm alongside Novo Nordisk’s Wegovy in the Phase 2b PLATEAU trial in older adults with obesity.

Veru Inc. (NASDAQ:VERU) has entered into a clinical supply agreement with Novo Nordisk A/S (NYSE:NVO) to support its upcoming Phase 2b PLATEAU study, which will investigate a combination treatment for obesity in older adults.

Eli Lilly knows that its GLP-1 windfall comes with an end date, so it is acting now to prepare.

A share price rally pushed ASML's market cap to $668 billion on Wednesday, beating a European record set by Novo Nordisk in June 2024.

The Dutch chipmaker eclipses Novo Nordisk's 2024 peak as AI infrastructure demand drives a 130% rally.

Danske Bank lifts Denmark outlook again as Novo Nordisk demand supports export growth.

There is light at the end of the tunnel.